SHINE Medical Technologies has completed a $150 million Series C-5 financing round led by Koch Disruptive Technologies (KDT), with participation from Fidelity Management & Research Company, Baillie Gifford and other new and current investors, the company announced recently.

“KDT is an incredible strategic partner for SHINE as we commercialize both diagnostic and therapeutic medical isotopes and work toward fusion-based nuclear waste recycling and clean energy production,” SHINE CEO Greg Piefer said in a statement.

According to a release, the funds will support SHINE’s commercialization of its diagnostic and therapeutic medical isotope technologies and position the company for future growth as it works toward developing new fusion-based technology applications.